Replies to post #9382 on Arch Therapeutics Inc (ARTH)

[Polyphemus]

On target. Some questions are: If there is any deal with a distributor that involves a cash payment for rights, either in US or OUS, one doesn't have to be concerned about extending the runway....correct?

What would $2M of additional funds be used for? Too little for product development. ARTH has spent over $30M and produced a wound dressing. Any hint about uses of cash beyond G&A?

[Regis999]

Total Outstanding Warrants 25,983,135
Total Exercise Cash $ 16,791,236
Average price per share $ .64

Total Cash raised since inception of Company $ 32,451,250

Market cap fully diluted $ 62,491,041

For every one dollar raised by ARTH it is now valued at $ 1.93

Employees since 2016 8 Employees

Study my previous post on Closure Medical Corporation Versus ARTH



***************************************Outstanding***Price Per Share
Warrant Series D Expires 6/30/20 8,974,389 $ .25
Warrant Series E Expires 5/26/21 4,214,582 $ .438
Warrant Series F Expires 2/20/22 5,991,664 $ .75
Warrant Series G Expires 6/29/23 6,802,500 $ .70
Warrant Series H Expires 5/14/24 8,615,384 $ .40

Series D % Exercised 37.6%
Series E % Exercised 40.3%
Series F % Exercised 0%
Series G % Exercised 0%
Series H % Exercised 0%